Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
November 13 2024 - 10:14AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2024
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
BLOCK LISTING SIX MONTHLY RETURN
Date: 13
November 2024
|
Name
of applicant:
|
GSK
plc
|
|
Name of
scheme:
|
GlaxoSmithKline
plc 2017 Deferred Annual Bonus Plan
|
|
Period
of return:
|
From:
|
1 May
2024
|
To:
|
31
October 2024
|
|
Balance
of unallotted securities under scheme(s) from previous
return:
|
115,518
|
|
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
0
|
|
Less: Number
of securities issued/allotted under
scheme(s) during period (see UKLR 20.6.7G):
|
0
|
|
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
115,518
|
|
Name
of applicant:
|
GSK
plc
|
|
Name of
scheme:
|
GlaxoSmithKline
plc Share Save Plan 2012
|
|
Period
of return:
|
From:
|
1 May
2024
|
To:
|
31
October 2024
|
|
Balance
of unallotted securities under scheme(s) from previous
return:
|
673,024
|
|
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
0
|
|
Less: Number
of securities issued/allotted under
scheme(s) during period (see UKLR 20.6.7G):
|
155,786
|
|
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
517,238
|
|
Name
of applicant:
|
GSK
plc
|
|
Name of
scheme:
|
GlaxoSmithKline
plc Share Save Plan 2022
|
|
Period
of return:
|
From:
|
1 May
2024
|
To:
|
31
October 2024
|
|
Balance
of unallotted securities under scheme(s) from previous
return:
|
995,257
|
|
Plus: The
amount by which the block scheme(s) has been increased since the
date of the last return (if any increase has been applied
for):
|
0
|
|
Less: Number
of securities issued/allotted under
scheme(s) during period (see UKLR 20.6.7G):
|
19,867
|
|
Equals: Balance
under scheme(s) not yet issued/allotted at end of
period:
|
975,390
|
|
Name of
contact:
|
Victoria
Whyte
|
|
Telephone
number of contact:
|
020
8047 5000
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
13, 2024
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Nov 2024 to Dec 2024
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Dec 2023 to Dec 2024
